"It's Like a Marathon": A Qualitative Study of Symptom Burden and Adaptation Among Patients with Oxaliplatin-Induced Peripheral Neuropathy During Treatment.
- 1School of Nursing, Xuzhou Medical University, Xuzhou 221000, China.
- 2Department of Nursing, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China.
Abstract
Oxaliplatin-induced peripheral neuropathy (OIPN) can substantially affect patients' everyday lives, yet less is known about how patients appraise and adapt to these symptoms during ongoing treatment. This qualitative study explored how patients appraise and adapt to OIPN during ongoing treatment and how these experiences relate to considerations about treatment continuation. Fifteen patients receiving oxaliplatin-based chemotherapy at a tertiary hospital in Shanghai, China, completed face-to-face semi-structured interviews. Four interrelated themes were constructed: (1) evolving and embodied symptom experiences, (2) disruption and contraction of everyday life, (3) appraising and adapting to symptom uncertainty, and (4) balancing symptom burden and perceived treatment value. Participants described recurrent symptoms that could become increasingly persistent, disrupt everyday functioning, and create uncertainty about recovery. They developed individualized strategies to manage symptoms and differed in what they considered tolerable. Considerations about treatment continuation reflected the interaction of symptom burden, perceived manageability, and perceived treatment value. These findings highlight the importance of understanding how patients appraise and adapt to OIPN during treatment. They may help oncology nurses identify support needs and provide individualized information as treatment progresses.
Related
- Baseline Peripheral Neuropathy Predicts Clinically Significant Neuropathy During Paclitaxel Treatment Following Oxaliplatin-based Chemotherapy.
- Emerging Therapeutic Targets in Oxaliplatin-Induced Acute Peripheral Neuropathy: Biochemical Protection by Organoselenium via Redox and Ionic Regulation.
- Zdhhc14 promotes pyroptosis in the dorsal root ganglion of oxaliplatin‐induced peripheral neuropathy mice by enhancing GBP5 palmitoylation and suppressing its ubiquitination
- Impact of neuropathy severity on hand function, strength, and dexterity in patients with oxaliplatin-induced peripheral neuropathy.
- Topical herbal medicine as treatment for chemotherapy-induced peripheral neuropathy: a systematic review of randomized controlled trials
BibTeX
@article{zhang2026like,
title = {{"It's Like a Marathon": A Qualitative Study of Symptom Burden and Adaptation Among Patients with Oxaliplatin-Induced Peripheral Neuropathy During Treatment.}},
author = {Yi Zhang and Jing Han and Wen Gong and Xiaoxia Qiu},
journal = {Current oncology (Toronto, Ont.)},
year = {2026},
month = oct,
doi = {10.3390/curroncol33100620},
url = {https://europepmc.org/article/MED/42930187},
note = {CC BY},
}
RIS
TY - JOUR
TI - "It's Like a Marathon": A Qualitative Study of Symptom Burden and Adaptation Among Patients with Oxaliplatin-Induced Peripheral Neuropathy During Treatment.
AU - Yi Zhang
AU - Jing Han
AU - Wen Gong
AU - Xiaoxia Qiu
PY - 2026
DA - 2026/10/14
JO - Current oncology (Toronto, Ont.)
DO - 10.3390/curroncol33100620
UR - https://europepmc.org/article/MED/42930187
AB - Oxaliplatin-induced peripheral neuropathy (OIPN) can substantially affect patients' everyday lives, yet less is known about how patients appraise and adapt to these symptoms during ongoing treatment. This qualitative study explored how patients appraise and adapt to OIPN during ongoing treatment and how these experiences relate to considerations about treatment continuation. Fifteen patients receiving oxaliplatin-based chemotherapy at a tertiary hospital in Shanghai, China, completed face-to-face semi-structured interviews. Four interrelated themes were constructed: (1) evolving and embodied symptom experiences, (2) disruption and contraction of everyday life, (3) appraising and adapting to symptom uncertainty, and (4) balancing symptom burden and perceived treatment value. Participants described recurrent symptoms that could become increasingly persistent, disrupt everyday functioning, and create uncertainty about recovery. They developed individualized strategies to manage symptoms and differed in what they considered tolerable. Considerations about treatment continuation reflected the interaction of symptom burden, perceived manageability, and perceived treatment value. These findings highlight the importance of understanding how patients appraise and adapt to OIPN during treatment. They may help oncology nurses identify support needs and provide individualized information as treatment progresses.
SN - 1198-0052
SN - 1718-7729
ER -